Literature DB >> 8732729

Cost-effective therapy for hypertension.

W Barrie1.   

Abstract

The costs of treating hypertension are out of control. The Joint National Committee on the Detection, Evaluation, and Treatment of High Blood Pressure and others recommend the use of diuretics and beta-blockers as first-line agents. Newer drugs such as calcium channel blockers, alpha-blockers, and angiotensin-converting-enzyme inhibitors have improved metabolic profiles, but have not been proved in long-term, randomized, controlled trials to reduce morbidity and mortality. Our General Medicine Clinic has gradually shifted toward prescribing the newer agents. We reviewed our drug use, evaluated the literature, and made recommendations in the form of guidelines. Clinicians' concerns included quality-of-life issues, sexual dysfunction, metabolic changes--lipids, potassium, insulin resistance--and others. These concerns were addressed, and a consensus was reached. Our goal is to streamline therapy, reduce costs, and provide proven effective medication.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8732729      PMCID: PMC1303503     

Source DB:  PubMed          Journal:  West J Med        ISSN: 0093-0415


  30 in total

1.  Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study.

Authors:  J Wikstrand; I Warnold; G Olsson; J Tuomilehto; D Elmfeldt; G Berglund
Journal:  JAMA       Date:  1988-04-01       Impact factor: 56.272

2.  Drug treatment of hypertension in the elderly: a meta-analysis.

Authors:  J T Insua; H S Sacks; T S Lau; J Lau; D Reitman; D Pagano; T C Chalmers
Journal:  Ann Intern Med       Date:  1994-09-01       Impact factor: 25.391

Review 3.  Quality of life and cost-effectiveness in the treatment of hypertension.

Authors:  I Wiklund
Journal:  J Clin Pharm Ther       Date:  1994-04       Impact factor: 2.512

Review 4.  Can the cost of care be contained and quality of care maintained in the management of hypertension?

Authors:  M Moser
Journal:  Arch Intern Med       Date:  1994-08-08

5.  Diuretic therapy for hypertension and the risk of primary cardiac arrest.

Authors:  D S Siscovick; T E Raghunathan; B M Psaty; T D Koepsell; K G Wicklund; X Lin; L Cobb; P M Rautaharju; M K Copass; E H Wagner
Journal:  N Engl J Med       Date:  1994-06-30       Impact factor: 91.245

6.  Developing guidelines for local use: algorithms for cost-efficient outpatient management of cardiovascular disorders in a VA Medical Center.

Authors:  J N Aucott; A L Taylor; J T Wright; M B Ganz; C S Landefeld; E I Pelecanos; A M Carrol; R C Dombrowski; K J van Why; R Lederman
Journal:  Jt Comm J Qual Improv       Date:  1994-01

Review 7.  Hypertension and diabetes: epidemiologic aspects as a guide to management.

Authors:  J H Fuller
Journal:  J Cardiovasc Pharmacol       Date:  1993       Impact factor: 3.105

8.  An open one-year comparison of doxazosin and prazosin for mild to moderate essential hypertension.

Authors:  D Torvik; H P Madsbu
Journal:  Am J Cardiol       Date:  1987-05-29       Impact factor: 2.778

9.  Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure.

Authors:  T Hannedouche; P Landais; B Goldfarb; N el Esper; A Fournier; M Godin; D Durand; J Chanard; F Mignon; J M Suo
Journal:  BMJ       Date:  1994-10-01

Review 10.  Do non-potassium-sparing diuretics increase the risk of sudden cardiac death in hypertensive patients? Recent evidence.

Authors:  A W Hoes; D E Grobbee; T M Peet; J Lubsen
Journal:  Drugs       Date:  1994-05       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.